- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04397588
Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19 (ECMO-SARS)
Extracorporeal Membrane Oxygenation (ECMO) as a Therapeutic Option in Severe Form of COVID-19: a Nationwide Cohort Study
Study Overview
Status
Detailed Description
The main objective of this study is to evaluate the hospital survival of COVID-19 patients supported by venovenous or venoarterial ECMO in a multicenter registry.
The secondary objectives are to describe the characteristics of COVID-19 patients who have received ECMO support, to identify the risk factors associated with hospital mortality, to analyze the outcomes after ECMO weaning including survival at day 28 and day 90, and to analyze the utility of a circulatory support mobile unit in a severe pandemic
Inclusions are both prospective and retrospective in order to collect data over the whole pandemic
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49933
- Angers University Hospital
-
Besançon, France, 25030
- Besançon Hospital
-
Brest, France, 29200
- Brest University Hospital
-
Caen, France, 14033
- CAEN University Hospital
-
Clermont-Ferrand, France, 63003
- Clermont Ferrand University Hospital
-
Créteil, France, 94000
- APHP Henri Mondor Paris University Hospital
-
Dijon, France, 21079
- Dijon University Hospital
-
La Roche-sur-Yon, France, 85000
- Vendée Hospital
-
La Tronche, France, 38700
- Grenoble university hospital
-
Le Kremlin-Bicêtre, France, 94275
- APHP Kremli Bicetre Paris University Hospital
-
Le Plessis-Robinson, France, 92350
- Marie Lannelongue Hospital
-
Lens, France, 62307
- Lens Hospital
-
Lille, France, 59000
- Lille University Hospital
-
Limoges, France, 87042
- Limoges university hospital
-
Lyon, France, 69337
- Clinique de la Sauvegarde
-
Lyon, France, 69500
- Lyon University Hospital
-
Marseille, France, 13009
- Clairval Hospital
-
Marseille, France, 13003
- Marseille Européen Hospital
-
Marseille, France, 13005
- APHM la Timone- Marseille University Hospital
-
Metz, France, 45000
- Metz University Hospital
-
Montpellier, France, 34090
- Montpellier University Hospital
-
Mulhouse, France, 68051
- Emile Muller Hospital
-
Nancy, France, 54511
- Nancy University Hospital
-
Nantes, France, 44000
- Nantes university hospital
-
Neuilly-sur-Seine, France, 92200
- Ambroise Paré Hospital
-
Nîmes, France, 30029
- Nîmes University Hospital
-
Paris, France, 75014
- Institut Mutualiste Montsouris
-
Paris, France, 75015
- APHP Hopital Européen Georges Pompidou - Paris University Hospital
-
Paris, France, 75015
- APHP necker Paris University Hospital
-
Paris, France, 75018
- APHP Bichat - Paris University Hospital
-
Paris, France, 75651
- APHP La Pitié Salpêtrière Paris University Hospital
-
Pessac, France, 33604
- Bordeaux University Hospital
-
Poitiers, France, 86000
- Poitiers University Hospital
-
Reims, France, 51092
- Reims University Hospital
-
Rennes, France, 35000
- Rennes University Hospital
-
Rouen, France, 76031
- Rouen University Hospital
-
Saint-Brieuc, France, 22027
- Saint brieuc Hospital
-
Saint-Denis, France, 97400
- La Réunion University Hospital
-
Saint-Etienne, France, 42000
- Saint Etienne University Hospital
-
Saint-Nazaire, France, 44606
- Saint Nazaire Hospital
-
Strasbourg, France, 67091
- Strasbourg University Hospital
-
Toulouse, France, 31000
- Toulouse University Hospital - Rangueil Hospital
-
Tours, France, 37044
- Tours University Hospital
-
Vannes, France, 56000
- Bretagne Atlantique Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All COVID-19 patients, adults or children,
- Tested positive by RT-PCR for SARS-CoV2 (nasopharyngeal swabs, sputum, endotracheal aspiration, bronchoalveolar lavage or stool sample) and / or with a diagnosis made on chest CT findings,
- Supported by venovenous or venoarterial ECMO
Exclusion Criteria:
- Temporary legally protected Adults over a set period or waiting for protection supervision, guardianship
- Patients or proxies who express their opposition to study participation
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hospital mortality
Time Frame: up to 90 days
|
Hospital mortality
|
up to 90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality Day 28
Time Frame: Day 28
|
Mortality Day 28
|
Day 28
|
|
Mortality Day 90
Time Frame: Day 90
|
Mortality Day 90
|
Day 90
|
|
Ventilator-free days
Time Frame: Day 28
|
Ventilator-free days
|
Day 28
|
|
Intensive care unit-free days
Time Frame: Day 28
|
ICU-free days
|
Day 28
|
|
Hospital-free days
Time Frame: Day 28
|
Hospital-free days
|
Day 28
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nicolas Nesseler, doctor, Rennes University Hospital
- Principal Investigator: André Vincentelli, professor, University Hospital, Lille
Publications and helpful links
General Publications
- Mansour A, Flecher E, Schmidt M, Rozec B, Gouin-Thibault I, Esvan M, Fougerou C, Levy B, Porto A, Ross JT, Para M, Manganiello S, Lebreton G, Vincentelli A, Nesseler N; ECMOSARS Investigators. Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study. Intensive Care Med. 2022 Aug;48(8):1039-1052. doi: 10.1007/s00134-022-06794-y. Epub 2022 Jul 13.
- Nesseler N, Mansour A, Schmidt M, Para M, Porto A, Falcoz PE, Mongardon N, Fougerou C, Ross JT, Beurton A, Gaide-Chevronnay L, Guinot PG, Lebreton G, Flecher E, Vincentelli A, Massart N; ECMOSARS Investigators; SFAR Research Network. Healthcare-associated infections in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study. Crit Care. 2024 Feb 20;28(1):54. doi: 10.1186/s13054-024-04832-3.
- Massart N, Guervilly C, Mansour A, Porto A, Flecher E, Esvan M, Fougerou C, Fillatre P, Duburcq T, Lebreton G, Para M, Stephan F, Hraiech S, Ross JT, Schmidt M, Vincentelli A, Nesseler N; Extracorporeal Membrane Oxygenation for Respiratory Failure and/or Heart failure related to Severe Acute Respiratory Syndrome Coronavirus 2 (ECMOSARS) Investigators. Impact of Prone Position in COVID-19 Patients on Extracorporeal Membrane Oxygenation. Crit Care Med. 2023 Jan 1;51(1):36-46. doi: 10.1097/CCM.0000000000005714. Epub 2022 Nov 11.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Heart Diseases
- Respiratory Tract Infections
- Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Pneumonia, Viral
- Pneumonia
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- Cardiomyopathies
- COVID-19
- Heart Failure
- Myocarditis
- Severe Acute Respiratory Syndrome
Other Study ID Numbers
- 35RC20_8979 ECMO-SARS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2
-
A.O. Ospedale Papa Giovanni XXIIICompletedSevere Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 InfectionItaly
-
Imam Abdulrahman Bin Faisal UniversityDammam Medical Complex; Institute for Research and medical consultations (IRMC)UnknownHospitalized Patients | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection) | Laboratory-confirmed SARS-CoV 2 InfectionSaudi Arabia
-
ANRS, Emerging Infectious DiseasesRecruitingSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)France, Martinique
-
University of PecsHungarian Ministry of Innovation and TechnologyTerminatedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Hungary
-
Saint Francis CareCompletedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | COVID | CoronavirusUnited States
-
University Hospital, Basel, SwitzerlandCompletedSevere-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2)Switzerland
-
Cogna Technology Solutions LLCNovavaxCompletedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)United Arab Emirates
-
Apsen Farmaceutica S.A.Federal University of São PauloWithdrawnCoronavirus Infections | SARS-CoV 2 | Pulmonary Disease | SARS (Severe Acute Respiratory Syndrome)Brazil
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Oswaldo Cruz FoundationNot yet recruitingSevere Acute Respiratory Syndrome (SARS-CoV-2 Virus)
-
Goethe UniversityNationwide Network of University Medicine (NUM) on Covid-19RecruitingSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Germany